# AstraZeneca: Phase 1 study closed enrollment, 13 enrolled (Advanced Solid Tumor, Metastatic Colorectal Carcinoma)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours |
| NCT ID | NCT06147037 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Advanced Solid Tumor; Metastatic Colorectal Carcinoma; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Gastric Cancer |
| Intervention types | drug |
| Target enrollment | 13 |
| Site countries | United States, Canada |
| Posted | 2023-11-27 |
| Planned start | 2024-07-31 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-30 |
| Last update posted | 2026-09-30 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06147037). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.